Alpha Tau Medical Ltd. (NASDAQ:DRTS) Receives Average Rating of "Hold" from Analysts

Key Points

• Analyst sentiment is mixed: Eight firms collectively rate Alpha Tau Medical “Hold,” with five buys, one hold and two sells. The average 12-month price target is $15.40.
• Alpha Tau Medical opened at $15.24, near its 12-month high of $15.79, but reported quarterly EPS of -$0.50, missing the consensus estimate of -$0.14.
• Insiders have been selling shares: Executives sold 100,371 shares worth approximately $1.21 million over the past 90 days, while institutional investors own just 2.65% of the company.

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) have been given a consensus recommendation of "Hold" by the eight research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.40.

A number of equities research analysts have recently issued reports on the company. Barclays upped their price target on Alpha Tau Medical from $17.00 to $30.00 and gave the company an "overweight" rating in a research report on Thursday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Alpha Tau Medical in a research note on Friday, July 17th. HC Wainwright upped their target price on Alpha Tau Medical from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Benchmark reaffirmed a "buy" rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Finally, Zacks Research lowered Alpha Tau Medical from a "hold" rating to a "strong sell" rating in a report on Tuesday, September 1st.

Alpha Tau Medical Stock Performance

NASDAQ:DRTS opened at $15.24 on Friday. The company has a market cap of $1.38 billion, a P/E ratio of -14.65 and a beta of 1.20. Alpha Tau Medical has a twelve month low of $3.43 and a twelve month high of $15.79. The company's 50-day moving average price is $13.75 and its 200-day moving average price is $10.63. The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.36). On average, sell-side analysts forecast that Alpha Tau Medical will post -1.05 earnings per share for the current fiscal year.

Insider Transactions at Alpha Tau Medical

In related news, CFO Raphi Levy sold 2,871 shares of the firm's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,352,700. This trade represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 100,371 shares of company stock worth $1,210,233 in the last ninety days. 39.50% of the stock is currently owned by company insiders.

Institutional Trading of Alpha Tau Medical

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical during the 1st quarter worth approximately $286,000. Principal Financial Group Inc. acquired a new position in Alpha Tau Medical in the first quarter valued at approximately $132,000. Finally, Everhart Financial Group Inc. purchased a new position in Alpha Tau Medical in the second quarter worth approximately $126,000. Hedge funds and other institutional investors own 2.65% of the company's stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.